San Diego, CA (PRWEB) June 17, 2013
Resource4thePeople announced today that it has created an information center to inform consumers about the latest information involving legal rights over allegations that the use of the popular antibiotics Zithromax and Zmax SR (azithromycin) can cause potentially fatal irregular heart rhythms.
Included on the site are links to free consultations for consumers seeking to determine what legal rights they may have to compensation in such cases.
The site also will include details from the May, 17, 2012 warning* by the U.S. Food and Drug Administration alerting patients and physicians of life-threatening side effects from the medications that may lead to irregular heart rhythms.
“These are serious health concerns that the FDA has addressed and we will continue to provide valuable information of interest to consumers who may be among the millions who have been or are considering being treated with these antibiotics,” said Resource4thePeople.
“The postings on this site also will include detailed information about who the FDA considers most at risk of suffering these dangerous side effects.”
Here is the link to the site:
“We encourage anyone who has been treated with Zithromax or ZmaxSR and suffered an arrhythmia to contact our nationwide network of attorneys for a complimentary consultation about their allegations,” said Resource4thePeople.
“As we await further findings about these medications our legal team will continue to aggressively monitor these developments and they will be posted on the new information center.”
Resource4thePeople also notes that there may be legal time limits involved in the filing of a Zithromax lawsuit over allegations of serious side effects so consumers are urged to seek a consultation as soon as possible.
Antibiotics are among the most prescribed medications and azithromycin is most commonly chosen by doctors to treat a variety of bacterial infections. The medications are most frequently used for bronchitis, pneumonia, chest infections, urinary tract and other common infections.
Resource4thePeople also notes that Canadian authorities have joined the FDA in issuing warnings about concerns that the use of these antibiotics may cause abnormal changes in the electrical activity of the heart.
The Canadian Broadcasting Company reported** on May 17, 2013 that Health Canada has issued a warning that a "small absolute increase in the risk of cardiovascular deaths was observed in patients taking azithromycin as compared to those who took no antibiotics and those who took amoxicillin in a recent study."
“The recent health warning issued in Canada that follows concerns issued by the FDA about Zithromax and the allegations of serious side effects has increased the number of inquiries we are receiving about legal rights,” said Resource4thePeople.
The increase in consumer inquiries stems from concerns about side effects from the antibiotics first issued in the FDA warning and a report published the same day in a respected medical journal*** about whether patients who use the medications are at higher risk of suffering cardiac problems.
“We have now added additional resources to investigate claims of alleged health problems caused by the use of the antibiotics sold as Zithromax, the Z-Pak and azithromycin,” said Resource4thePeople.
FDA officials said that they have been made aware of the study*** published in the New England Journal of Medicine in which medical researchers found a higher percentage of cardiovascular deaths among patients treated with azithromycin (Zithromax) than with other antibiotics or no drugs.
The FDA announced that it is reviewing the findings of this study and said it will inform health care professionals and consumers about the results of this review after its completion.
The FDA also passed on this information about the review and updated warnings on the medication’s labels about health risks:
“Azithromycin belongs to a class of antibacterial drugs called macrolides, which have been associated with cardiovascular effects; specifically, prolongation of the QT interval. In 2011, FDA reviewed macrolide drug labeling information related to QT interval prolongation and TdP.
“The WARNINGS AND PRECAUTIONS section of the Zmax drug label (azithromycin extended release for oral suspension) was revised in March 2012 to include new information regarding risk for QT interval prolongation, which appears to be low.
“The drug labels for clarithromycin and erythromycin also contain information about QT interval prolongation in the WARNINGS section. FDA is in the process of updating risk information in the drug labels for additional macrolide antibacterial drugs.”
The FDA also recommended that patients who are taking azithromycin should not stop taking their medicine without talking to their health care professional and that physicians “should be aware of the potential for QT interval prolongation and heart arrhythmias when prescribing or administering macrolides.”
“In its Safety Information Report the FDA also encouraged patients and health care professionals to report adverse events or side effects caused by the use of these medications to the agency,” said Resource4thePeople.
“While the FDA is fulfilling its role of monitoring the safety of drugs such as Zithromax we are responding to reports from patients who are seeking information about what their legal rights may be and we are committed to providing that information on a case-by-case basis.”
The New England Journal of Medicine study included research compiled from information accumulated from about 350,000 patients who were treated with azithromycin over a 15-year period and concluded that these patients were one and a half times more likely to suffer cardiovascular sudden death than patients treated with other antibiotics.
One of the factors that made Zithromax so popular was the fact that it could be taken as a five-day treatment while most other antibiotics are prescribed to be taken over a 10-day treatment plan.